An interventional study of Fractionated Stereotactic Radiosurgery (fSRS) and Neurosurgical Resection in Brain Metastasases, sponsored by Northwell Health. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Northwell Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Brain Neoplasms by Northwell Health — 8 open to participants now, 8 under way, 1 of them phase 3. Brain Neoplasms · Northwell Health.
Among the 14 studies in Brain Neoplasms by Northwell Health, this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 5 with no phase, and was the 14th registered.
2,443 studies on the registry are indexed under Brain Neoplasms; 545 are open to participants now.
Browse Brain Neoplasms studies →8 of the 14 studies in Brain Neoplasms by Northwell Health are open now, in 1 country. Recruiting first, the newest first:
Northwell Health · Sites in United States
Healthy volunteers
Northwell Health · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18–74
By country, each count listing its studies:
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 1
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 40 across 1,834 interventional studies indexed under Brain Neoplasms.
Median enrollment 30 across the 14 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Northwell Health is the lead sponsor of 476 studies on the registry; 108 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 23 (50%) have results posted.
2 of the studies in Brain Neoplasms by Northwell Health that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT05979064Northwell HealthOmental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Brain Neoplasms by Northwell Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot study investigates a new approach for patients with metastatic cancer that has spread to the brain (brain metastases) who are already planned to receive both fractionated stereotactic radiosurgery (fSRS) and brain surgery as standard treatment for their condition. Usually, surgery comes first, followed by radiation. However, post-operative radiation can sometimes lead to the cancer returning in the area, spreading to the brain's lining (LMD), or causing side effects from radiation (RN). This study hypothesizes that delivering fSRS before surgery may improve outcomes by enabling more accurate targeting, reducing tumor spillage, and potentially decreasing RN, while improving treatment compliance. The study is specifically testing the sequence of these two standard treatments.
This is a single-arm, prospective study enrolling 12 adult participants (age >18) with 1-5 brain metastases, where one main tumor (between 2.0-5.0 cm diameter) requires surgical resection. Participants will receive fSRS (27 Gy in 3 fractions) approximately one week prior to surgery, as part of the study's approach. Throughout the study, participants will also have regular brain MRI scans to monitor their condition and complete tests to check memory and thinking skills (like the MoCA test) at various points.
The main goal is to see how well the cancer is controlled at the surgery site (called local freedom from progression, or FFP) over 6, 12, 18, and 24 months post-operatively. Secondary outcomes include rates of LMD and RN. Safety (adverse events, toxicities) will be continuously monitored by an independent Data Safety Monitoring Committee (DSMC). Each participant will be in the study for 2 years.
This research aims to provide preliminary data to inform future larger, randomized trials, ultimately improving treatment strategies for patients with metastatic brain cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Previous cranial radiotherapy, including whole-brain radiotherapy or stereotactic radiosurgery (SRS), to the planned resection site (index lesion). Repeat radiosurgery to the same location/lesion is not permitted on this protocol.
Note: Prior or current fSRS/SRS to other non-index lesions is allowed.
Note: Chemotherapy and immunotherapy outside of this window are allowed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm consists of all enrolled participants who will receive fractionated stereotactic radiosurgery (fSRS) prior to neurosurgical resection of their brain metastasis. This approach investigates a modified sequence of two standard-of-care treatments for this condition, aiming to evaluate its safety and efficacy.
Radiation: Fractionated Stereotactic Radiosurgery (fSRS) · Procedure: Neurosurgical Resection
Pre-operative fSRS to a dose of 27 Gy in 3 fractions will be delivered to the index lesion every other day. These radiation treatments will be completed within 1 week (+/- 5 days) prior to surgical resection. This is a standard radiation procedure for brain metastases.
Surgical removal of the brain metastasis (index lesion) performed after completion of pre-operative fSRS. This is a standard surgical procedure for brain metastases.
Also known as: Brain Metastasis Resection
Local Freedom from Progression (FFP) within the Resection Cavity
The absence of new nodular contrast enhancement 2 mm or less from the resection cavity.
Time frame: 6, 12, 18, and 24 Months Post-Operative
Incidence of Leptomeningeal Disease (LMD)
Documented incidence of LMD on brain MRI imaging
Time frame: From post-operative MRI (48-72 hours after surgery) through every 3 months for 2 years
Incidence of Radiation Necrosis (RN)
Documented incidence of RN on brain MRI imaging
Time frame: From post-operative (48-72 hours after surgery) through every 3 months for 2 years
Change in Neurocognitive Function
Assessed using the Montreal Cognitive Assessment (MoCA) score
Time frame: Baseline, Post-Operative Visit, and Every 3 Months for 2 Years
Correlation of Pathologic Information Between Primary Cancer and Resected Brain Metastasis
Comparison of pathological characteristics of resected brain metastasis with the primary tumor
Time frame: Between Surgery and Post-Operative Visit
Correlation of Extent of Surgical Resection with Survival Outcomes
Evaluation of the Association between extent of surgical resection and Progression-Free Survival (PFS) and Overall Survival (OS)
Time frame: From study registration until 2 years post-operative or death
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — A formal plan for sharing individual participant data (IPD) has not been developed or approved for this pilot study. Participant confidentiality and privacy are strictly maintained, and study data will be transmitted and stored internally at the Northwell Health Cancer Institute (NHCI) in a de-identified format for statistical analysis and scientific reporting. Results will be disseminated through publications that do not contain identifying information.
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
Of 308 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 24 months is below that.
Counting every sponsor, half of 319 studies reached it within 64 months; a quarter within 35 and three quarters within 125.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.